Another Fatal-Disease Drug in Limbo

A federal advisory panel votes against Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIAAn advisory panel for the US Food and Drug Administration (FDA) voted this week (April 25) that Sarepta Therapeutics’s eteplirsen has not been proven effective in the treatment of Duchenne muscular dystrophy (DMD), a rare and fatal disease for which there is currently know FDA-approved therapy. The news follows on the heels of the agency’s decision not to approve two other experimental DMD drugs, including BioMarin Pharmaceutical’s drisapersen, which received a similar assessment by an advisory panel last November. At that time, and leading up to this week’s meeting, patients and their families made emotional pleas for the therapies’ approvals, claiming that the treatments had helped improve the patients’ conditions in clinical trials. The FDA will make its final decision on eteplirsen by the end of next month, STAT News reported.

The vote was not unanimous, however; the finding that eteplirsen is not effective was reached by a vote of just 7-to-3, with three abstentions. Indeed, the FDA’s Janet Woodcock acknowledged that “it’s possible to reach different conclusions based on the data presented today,” according to STAT. “Failing to approve a drug that actually works in devastating diseases—these consequences are extreme,” she added.

The main concern was that the main clinical trial to demonstrate the drug’s efficacy included just 12 patients and short, six-minute walking tests. “I felt this wasn’t a well-controlled study,” said panel chairman G. Caleb Alexander, an associate epidemiology professor at the Johns Hopkins School of Public Health (via The Wall Street Journal). But the testimony of parents who believed that eteplirsen had ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Jef Akst

    Jef Akst was managing editor of The Scientist, where she started as an intern in 2009 after receiving a master’s degree from Indiana University in April 2009 studying the mating behavior of seahorses.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide